Back to results
US 12,497,608 B2Granted
Gene therapy for Alzheimer's disease
AssigneesThe Brigham and Women's Hospital, Inc., The General Hospital Corporation
InventorsJie Shen, Raymond J. Kelleher, III
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things, methods for using presenilin based gene therapy to treat neurodegenerative dementia including, but not limited to Alzheimers disease, frontotemporal dementia, frontotemporal lobar degeneration, Picks disease, Lewy body dementia, memory loss, and cognitive impairment including mild cognitive impairment (MCI).
Claims3
A method of treating one or more symptoms of familial Alzheimer's Disease in a human subject having human presenilin-1 (PSEN1) gene mutation L435F as compared to SEQ ID NO:
- 17, the method comprising administering by intracerebroventricular injection to the subject an AAV9 vector comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO:
- 5 or SEQ ID NO:
- 6 operably linked to a synapsin I or an alpha-calcium/calmodulin kinase 2A promoter.
Dependencies are inferred from the claim text.